Business Model Breakdown
How Caribou Biosciences Inc Makes Money
CRBU
Market Cap
$213M
Annual Revenue
$9M
Profit Margin
-1327.4%
Employees
147
The Short Version
Caribou Biosciences is a clinical-stage biotechnology company developing universal, 'off-the-shelf' CAR-T cell therapies for cancer. Unlike personalized treatments that use a patient's own cells, Caribou leverages its proprietary CRISPR genome-editing technology to engineer donor-derived cells, making these advanced therapies more broadly accessible, scalable, and potentially more cost-effective. The company currently generates minimal revenue, relying on research grants and collaborations, with its future entirely dependent on the successful clinical development, regulatory approval, and eventual commercialization or out-licensing of its drug candidates.
Where the Revenue Comes From
Research Collaboration & License Revenue (~100% of current revenue)
Who buys: Future customers (post-approval) will be hospitals and cancer treatment centers, and potentially pharmaceutical partners for licensing.
Why It Works (Competitive Advantages)
- ✔Proprietary CRISPR genome-editing (chRDNA) platform enabling 'off-the-shelf' therapies
- ✔Early clinical data for CB-011 (Multiple Myeloma) showing high response rates (92% ORR)
- ✔FDA RMAT designation for CB-011, expediting regulatory pathway
Economic Moat: Narrow (Intangible Assets/IP (CRISPR chRDNA platform and associated patents), Research & Development Capabilities (expertise in advanced gene-editing))
What Our Analysis Says
DVR Score as of April 21, 2026
Caribou Biosciences (CRBU) presents a high-risk, high-reward profile driven by its innovative CRISPR 'off-the-shelf' CAR-T platform. The significant boost to its score reflects the recent FDA RMAT designation for CB-011, based on compelling Phase 1 data (92% ORR). This materially de-risks a key asset and accelerates its path to market leadership in a vast oncology segment. Strong Q4 2025 earnings and analyst upgrades further contribute to positive momentum. While the company faces substantial financial hurdles, including a high cash burn ($200-220M for 2026) and inevitable dilution, its strategic positioning and competitive advantages in a high-growth market justify its 10x potential within 3-5 years, despite current unprofitability and financial fragility.